These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 31504702)

  • 1. Drug-Drug Interactions of Glecaprevir and Pibrentasvir Coadministered With Human Immunodeficiency Virus Antiretrovirals.
    Kosloski MP; Oberoi R; Wang S; Viani RM; Asatryan A; Hu B; Ding B; Qi X; Kim EJ; Mensa F; Kort J; Liu W
    J Infect Dis; 2020 Jan; 221(2):223-231. PubMed ID: 31504702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection.
    Flamm S; Reddy KR; Zadeikis N; Hassanein T; Bacon BR; Maieron A; Zeuzem S; Bourliere M; Calleja JL; Kosloski MP; Oberoi RK; Lin CW; Yu Y; Lovell S; Semizarov D; Mensa FJ
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):527-535.e6. PubMed ID: 30012435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection.
    Ng TI; Pilot-Matias T; Tripathi R; Schnell G; Krishnan P; Reisch T; Beyer J; Dekhtyar T; Irvin M; Lu L; Asatryan A; Campbell A; Yao B; Lovell S; Mensa F; Lawitz EJ; Kort J; Collins C
    Viruses; 2018 Aug; 10(9):. PubMed ID: 30154359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three Cases.
    Sho T; Suda G; Kimura M; Shimazaki T; Maehara O; Shigesawa T; Suzuki K; Nakamura A; Ohara M; Umemura M; Izumi T; Kawagishi N; Baba M; Nakai M; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N;
    Intern Med; 2019 Mar; 58(6):797-802. PubMed ID: 30449808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study.
    Rockstroh JK; Lacombe K; Viani RM; Orkin C; Wyles D; Luetkemeyer AF; Soto-Malave R; Flisiak R; Bhagani S; Sherman KE; Shimonova T; Ruane P; Sasadeusz J; Slim J; Zhang Z; Samanta S; Ng TI; Gulati A; Kosloski MP; Shulman NS; Trinh R; Sulkowski M
    Clin Infect Dis; 2018 Sep; 67(7):1010-1017. PubMed ID: 29566246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection.
    Mensa FJ; Lovell S; Pilot-Matias T; Liu W
    Future Microbiol; 2019 Jan; 14():89-110. PubMed ID: 30499343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glecaprevir/Pibrentasvir: The First 8-Week, Pangenotypic HCV Treatment Regimen for Patients 12 Years of Age and Older.
    Huff J; Andersen R
    Ann Pharmacother; 2020 Mar; 54(3):262-276. PubMed ID: 31537106
    [No Abstract]   [Full Text] [Related]  

  • 8. Translation of In Vitro Transport Inhibition Studies to Clinical Drug-Drug Interactions for Glecaprevir and Pibrentasvir.
    Kosloski MP; Bow DAJ; Kikuchi R; Wang H; Kim EJ; Marsh K; Mensa F; Kort J; Liu W
    J Pharmacol Exp Ther; 2019 Aug; 370(2):278-287. PubMed ID: 31167814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, Safety, and Tolerability of Glecaprevir and Pibrentasvir in Healthy White, Chinese, and Japanese Adult Subjects.
    Lin CW; Dutta S; Ding B; Wang T; Zadeikis N; Asatryan A; Kort J; Campbell A; Podsadecki T; Liu W
    J Clin Pharmacol; 2017 Dec; 57(12):1616-1624. PubMed ID: 28800195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No Clinically Relevant Drug-Drug Interactions between Methadone or Buprenorphine-Naloxone and Antiviral Combination Glecaprevir and Pibrentasvir.
    Kosloski MP; Zhao W; Asatryan A; Kort J; Geoffroy P; Liu W
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28807904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.
    Asselah T; Kowdley KV; Zadeikis N; Wang S; Hassanein T; Horsmans Y; Colombo M; Calinas F; Aguilar H; de Ledinghen V; Mantry PS; Hezode C; Marinho RT; Agarwal K; Nevens F; Elkhashab M; Kort J; Liu R; Ng TI; Krishnan P; Lin CW; Mensa FJ
    Clin Gastroenterol Hepatol; 2018 Mar; 16(3):417-426. PubMed ID: 28951228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers.
    Feng HP; Caro L; Fandozzi C; Chu X; Guo Z; Talaty J; Panebianco D; Dunnington K; Du L; Hanley WD; Fraser IP; Mitselos A; Denef JF; De Lepeleire I; de Hoon JN; Vandermeulen C; Marshall WL; Jumes P; Huang X; Martinho M; Valesky R; Butterton JR; Iwamoto M; Yeh WW
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic Interactions and Safety of Coadministration of Glecaprevir and Pibrentasvir in Healthy Volunteers.
    Lin CW; Dutta S; Zhao W; Asatryan A; Campbell A; Liu W
    Eur J Drug Metab Pharmacokinet; 2018 Feb; 43(1):81-90. PubMed ID: 28688001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Virus: Part 1 of the DORA Study.
    Jonas MM; Squires RH; Rhee SM; Lin CW; Bessho K; Feiterna-Sperling C; Hierro L; Kelly D; Ling SC; Strokova T; Del Valle-Segarra A; Lovell S; Liu W; Ng TI; Porcalla A; Gonzalez YS; Burroughs M; Sokal E
    Hepatology; 2020 Feb; 71(2):456-462. PubMed ID: 31254392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c.
    Ramirez S; Fernandez-Antunez C; Mikkelsen LS; Pedersen J; Li YP; Bukh J
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Key drug-drug interactions with direct-acting antiviral in HIV-HCV coinfection.
    El-Sherif O; Khoo S; Solas C
    Curr Opin HIV AIDS; 2015 Sep; 10(5):348-54. PubMed ID: 26248122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the treatment of Hepatitis C.
    Hubbard H; Lawitz E
    Expert Rev Gastroenterol Hepatol; 2018 Jan; 12(1):9-17. PubMed ID: 29187007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-Drug Interactions of Tacrolimus or Cyclosporine With Glecaprevir and Pibrentasvir in Healthy Subjects.
    Kosloski MP; Zhao W; Li H; Pugatch D; Asatryan A; Kort J; Mensa FJ; Liu W
    Clin Pharmacol Drug Dev; 2019 Aug; 8(6):779-789. PubMed ID: 30861340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz, and tenofovir.
    Sabo JP; Kort J; Ballow C; Haschke M; Battegay M; Fuhr R; Girlich B; Schobelock M; Feifel U; Lang B; Li Y; Elgadi M
    Clin Infect Dis; 2014 Nov; 59(10):1420-8. PubMed ID: 25091302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glecaprevir + pibrentasvir for treatment of hepatitis C.
    Carrion AF; Martin P
    Expert Opin Pharmacother; 2018 Mar; 19(4):413-419. PubMed ID: 29465262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.